What is AELIX Therapeutics?
AELIX Therapeutics, headquartered in Barcelona, Spain, is a biotechnology company dedicated to advancing a novel therapeutic HIV vaccine. As a spin-off from the HIVACAT consortium, AELIX Therapeutics holds exclusive worldwide rights to the HTI immunogen, a key component in its development pipeline. The company's focus on cure and eradication strategies positions it at the forefront of HIV research, addressing a critical unmet medical need. The enterprise-level funding indicates a strong belief in the company's scientific approach and therapeutic potential.
How much funding has AELIX Therapeutics raised?
AELIX Therapeutics has raised a total of $12.8M across 1 funding round:
Series A
$12.8M
Series A (2016): $12.8M with participation from JJDC Inc., Ysios Capital, and Caixa Capital Risc
Key Investors in AELIX Therapeutics
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide. The firm provides resources to biotech ventures focused on developing novel therapies for high unmet medical needs, aiming to positively impact patients and society.
Caixa Capital Risc
CriteriaCaixa is a venture capital firm focused on investing in innovative startups at early stages, particularly in technology, biotechnology, and the industrial sector. They manage investments through Caixa Capital Risc and Criteria Venture Capital, directing resources into three specialized funds: Criteria Venture Tech, Criteria Bio Ventures, and Criteria Industrial Ventures.
JJDC Inc.
Undisclosed investor participating in the funding round.
What's next for AELIX Therapeutics?
With the recent major strategic investment, AELIX Therapeutics is poised to accelerate its clinical development programs. This capital infusion is expected to fuel the progression of its therapeutic HIV vaccine through crucial stages of testing and validation. The company's trajectory suggests a move towards scaling its operations and advancing towards potential commercialization, contingent on successful clinical outcomes. The strategic nature of this financing implies potential collaborations or partnerships that could further enhance its market position and research capabilities.
See full AELIX Therapeutics company page
